Human brain mapping · 2025
Single-Subject Network Analysis of FDOPA PET in Parkinson's Disease and Psychosis Spectrum.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Severino Mario, Schubert Julia J, Nordio Giovanna, Giacomel Alessio, Easmin Rubaida, Lao-Kaim Nick P, Selvaggi Pierluigi, Xu Zhilei, Pereira Joana B, Jauhar Sameer, Piccini Paola, Howes Oliver, Turkheimer Federico, Veronese Mattia, FDOPA PET Imaging Working Group Consortium
Аннотация
Greater understanding of individual biological differences is essential for developing more targeted treatment approaches to complex brain disorders. Traditional analysis methods in molecular imaging studies have primarily focused on quantifying tracer binding in specific brain regions, often neglecting inter-regional functional relationships. In this study, we propose a statistical framework that combines molecular imaging data with perturbation covariance analysis to construct single-subject networks and investigate individual patterns of molecular alterations. This framework was tested on [18F]-DOPA PET imaging as a marker of the brain dopamine system in patients with Parkinson's Disease (PD) and schizophrenia to evaluate its ability to classify patients and characterize their disease severity. Our results show that single-subject networks effectively capture molecular alterations, differentiate individuals with heterogeneous conditions, and account for within-group variability. Moreover, the approach successfully distinguishes between preclinical and clinical stages of psychosis and identifies the corresponding molecular connectivity changes in response to antipsychotic medications. Mapping molecular imaging networks presents a new and powerful method for characterizing individualized disease trajectories as well as for evaluating treatment effectiveness in future research.